April Chen is the Director of DMPK (Oncology) at AstraZeneca, where they lead the ADME team and collaborate cross-functionally to support oncology projects. They have a proven track record in advancing drug candidates to FDA approval, notably managing the SUL-DUR project and contributing to the success of ETX2514. April has held various positions including Principal Scientist at Entasis Therapeutics and Senior Associate Scientist at Amgen, focusing on DMPK, bioanalysis, and ADME assay development. Currently, they are pursuing a Bachelor's degree in Analytical Chemistry from the University of Science and Technology of China and a Master of Science in Analytical Chemistry from Rutgers, the State University of New Jersey.
This person is not in any teams
This person is not in any offices